Cancer is a disease we hear about often, affecting people in many forms. But not all cancers are the same, and some are so rare that even experts struggle to find information on them. Recently, I came across a case study of a young man diagnosed with an exceptionally rare form of cancer called Alveolar Soft Part Sarcoma (ASPS). This type of cancer, which accounts for less than 1% of all soft tissue sarcomas, mainly affects younger people in their teens and twenties and is challenging to treat. Here, I'll summarize what I learned about this unusual case and what it reveals about the difficulties doctors face with rare cancers.
ASPS is a type of cancer that
develops in the soft tissues, often beginning in the legs or buttocks and
sometimes in the head or neck. It's called "alveolar" because of the
microscopic structure of the tumour cells that form a pattern resembling
alveoli, or tiny sacs in the lungs. This is a slow-growing cancer, which may
sound better at first, but it’s not. Its slow nature makes it hard to detect
early, allowing it to spread to other parts of the body, mainly the lungs and
brain, before it's even found.
The study I read described a
24-year-old man who went to the doctor with mild pain in his left leg, which he
thought was a sports injury. But after months of worsening pain and swelling,
he finally got an MRI scan. The results were shocking: the scan showed a small,
dense mass in his thigh muscle. At first, the doctors thought it might be a
benign tumour, but after a biopsy, they discovered it was ASPS.
Unlike more common cancers, ASPS
doesn’t respond well to traditional chemotherapy or radiation. The reason is
that ASPS cells are slow-dividing and therefore harder to target with
treatments that are typically effective against fast-dividing cancer cells.
This was a big challenge for the medical team, who were left with very few
treatment options.
The doctors considered surgery to
remove the tumour, but ASPS is known to spread early. This young man's cancer
had already spread to his lungs by the time they discovered it. Unfortunately,
metastasis (spread to other areas) in ASPS patients is common, making complete
surgical removal nearly impossible. In this case, the medical team decided to
try a new targeted therapy called *Tivozanib*. Tivozanib is designed to stop
the growth of blood vessels that feed the tumour, slowing down its growth.
However, this treatment doesn’t
"cure" ASPS; it only tries to contain it. The young man responded
somewhat positively to Tivozanib, and the spread of the cancer slowed down, but
it didn't entirely stop. He still required constant monitoring, and his life
became centred around regular scans, blood tests, and consultations.
The emotional and physical impact on someone living with such a rare cancer is intense. Unlike common cancers, where there are established support groups and treatments, rare cancer patients often feel isolated. This young man shared that it was hard to explain his condition to friends and family because even he didn’t fully understand it. He would search online for information, but there wasn't much available on ASPS. The rare nature of the cancer also meant there were few clinical trials, which limited his treatment options even further.
One interesting part of his story
was how he tried to advocate for more awareness of rare cancers. He started a
blog to share his journey, detailing the highs and lows of his experience.
Through his blog, he connected with others around the world who had ASPS.
Although they were few in number, this small online community became a support
system for him, giving him strength and hope.
Studying rare cancers like ASPS
highlights the need for more research and awareness. Rare cancer cases often
don’t receive as much funding as more common types, which means fewer treatment
options and more uncertainty for patients. Many people, especially younger
patients, struggle to find the information and support they need.
This case also raises questions
about the role of genetic research. Since ASPS is linked to a specific genetic
mutation (involving the ASPSCR1-TFE3 fusion gene), genetic testing could
potentially help diagnose it earlier or even lead to future treatments.
Scientists are beginning to explore these areas, but it takes time, funding,
and a lot of research.
The story of this young man with
ASPS is both inspiring and heart breaking. It shows the challenges faced by
those with rare cancers and the importance of continued research. Though
treatments like Tivozanib offer some hope, there’s still a long way to go
before a cure or even effective treatment options are available for all rare
cancers.
Through cases like these, we can
learn the value of supporting rare cancer research. Even though only a small
percentage of people are affected, their lives are just as valuable, and the
advancements made in studying rare cancers could lead to discoveries that help
people with all kinds of cancers.
Reference list
Chang, X., Li, Y., Xue, X., Zhou, H. and Hou, L. (2021). The current management of alveolar soft part sarcomas. Medicine, 100(31), p.e26805. doi:https://doi.org/10.1097/md.0000000000026805.
Dao, E., Best, J., Hsiung, R.G., Sossi, V., Jacova, C., Tam, R. and Liu-Ambrose, T. (2017). EFFECTS OF AMYLOID ON CHANGES IN COGNITIVE AND PHYSICAL FUNCTION IN VASCULAR COGNITIVE IMPAIRMENT. Innovation in Aging, 1(suppl_1), pp.169–169. doi:https://doi.org/10.1093/geroni/igx004.656.
Oup.com. (2024). Available at: https://academic.oup.com/jjco/article/53/11/1009/7251339.
www.cancer.gov. (2023). Atezolizumab Shrinks Alveolar Soft Part Sarcomas - NCI. [online] Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2023/atezolizumab-effective-alveolar-soft-part-sarcoma.
x
Comments
Post a Comment